WO2006121822B1 - USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA - Google Patents

USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA

Info

Publication number
WO2006121822B1
WO2006121822B1 PCT/US2006/017336 US2006017336W WO2006121822B1 WO 2006121822 B1 WO2006121822 B1 WO 2006121822B1 US 2006017336 W US2006017336 W US 2006017336W WO 2006121822 B1 WO2006121822 B1 WO 2006121822B1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
prodrug
acceptable salt
formula
pharmaceutically acceptable
Prior art date
Application number
PCT/US2006/017336
Other languages
French (fr)
Other versions
WO2006121822A1 (en
Inventor
David W Old
Danny T Dinh
Robert M Burk
Original Assignee
Allergan Inc
David W Old
Danny T Dinh
Robert M Burk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, David W Old, Danny T Dinh, Robert M Burk filed Critical Allergan Inc
Priority to US11/569,696 priority Critical patent/US7674786B2/en
Publication of WO2006121822A1 publication Critical patent/WO2006121822A1/en
Publication of WO2006121822B1 publication Critical patent/WO2006121822B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of compounds of the general formula (I) or a pharmaceutically acceptable salt or a prodrug thereof for the treatment of IBD and glaucoma is disclosed, wherein Y, A, R, D, and n are as described. Methods, compositions, and medicaments related thereto are also disclosed.

Claims

AMENDED CLAIMS received by the International Bureau on 20 November 2006
1. A compound of the formula
Figure imgf000002_0001
or a pharmaceutically acceptable salt or a prodrug thereof, wherein a dashed line represents the presence or absence of a eovulcπt bond;
Y is a carboxylic acid, sulfonic acid, or phosphoric acid; or an amide or ester thereof comprising from 0 to 12 carbon atoms; or Y is a hydroxymethyl, or tctrazolyl functional group;
A is -(CH2)6-, cis -CH2CH=CH-(CH2)3-, or -CH2C≡C-(CH2)3- , whereirι 1 or 2 carbon atoms may be substituted with S or O; or A is -(CH2)m-Ar-(CH2)0- wherein Ar is substituted or uαsubstituted phenyl or monocyclic heteroaryl, the sum of m and o is from 1 to 4, and wherein one CH2 may be substituted with S or O;
X is S or O;
R is a hydrocarbyl or a hydroxyhydrocarbyl moiety comprising from 1 to 12 carbon atoms;
D is independently a moiety comprising from 1 to 6 non-hydrogen atoms; and n is an integer from 0 to 4.
2. The compound of claim 1, wherein n is 0.
3. The compound of claim 1 , wherein R comprises from 6 to 9 carbon atoms and a cyclic structure.
4. The compound of claim 3 of the formula
Figure imgf000002_0002
or a pharmaceutically acceptable salt, or a prodrug thereof. 5, The compound of claim 3 of the formula
Figure imgf000002_0003
or a pharmaceutically acceptable salt, or a prodrug thereof. 6, The compound of claim 1 of the formula
Figure imgf000003_0001
or a pharmaceutically acceptable salt, or a prodrug thereof. 7. The compound of claim 1 of the formula
Figure imgf000003_0002
or n pharmaceutically acceptable salt or a prodrug thereof.
S. The compound of claim 1 wherein A is -(CH2)6-, cis -CH2CH=CH-(CH2)3-, or -CH2C= C-(CH2)3- 9. The compound of claim 2 of the formula
Figure imgf000003_0003
or a pharmaceutically acceptable salt or a prodrug thereof. 10. The compound of claim 2 of the formula
Figure imgf000003_0004
or a pharmaceutically acceptable salt or a prodrug thereof; wherein R3, R4, and R5 are independently H or C1-6 alkyl
11. The compound of claim .10 wherein R" and R4 are methyl.
12. The compound of claim 11 of the formula
Figure imgf000004_0001
or a pharmaceutically acceptable salt or a prodrug thereof,
13. The compound of claim 2, wherein A is -(CH2)m -Ar-(CH2)o- wherein Ar is phenyl, the sum of m and o is from 1 to 4, and wherein one CH2 may be substituted with S or O.
14. The compound of claim 3 wherein A is -CH2-Ar-O-CH2-.
15. The compound of claim 1 of the formula
Figure imgf000004_0002
Figure imgf000005_0001
or a pharmaceutical acceptable salt or a prodrug thereof,
16. Use of a compound according to any one of claims 1 to 15 in the manufacture of a medicament for the treatment of glaucoma or ocular hypertension in a mammal.
17. A. composition comprising a compound, according to any one of claims 1 to 15, wherein said composition is a liquid which is ophthalmically acceptable.
PCT/US2006/017336 2005-05-06 2006-05-02 USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA WO2006121822A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/569,696 US7674786B2 (en) 2005-05-06 2006-05-02 Therapeutic β-lactams

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67840305P 2005-05-06 2005-05-06
US60/678,403 2005-05-06

Publications (2)

Publication Number Publication Date
WO2006121822A1 WO2006121822A1 (en) 2006-11-16
WO2006121822B1 true WO2006121822B1 (en) 2007-01-18

Family

ID=37011956

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/017336 WO2006121822A1 (en) 2005-05-06 2006-05-02 USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA

Country Status (1)

Country Link
WO (1) WO2006121822A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063033B2 (en) 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US7956051B2 (en) * 2008-01-24 2011-06-07 Allergan, Inc. Therapeutic amides and related compounds
US8440819B2 (en) 2008-02-22 2013-05-14 Allergan, Inc. Therapeutic substituted beta-lactams

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462968A (en) * 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5698598A (en) * 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
US6090847A (en) * 1997-11-21 2000-07-18 Allergan Sales, Inc. EP2 -receptor agonists as neuroprotective agents for the eye
MXPA04005555A (en) * 2002-03-18 2005-05-16 Pfizer Prod Inc Methods of treatment with selective ep4 receptor agonists.

Also Published As

Publication number Publication date
WO2006121822A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
WO2020227549A8 (en) MODULATORS OF THR-β AND METHODS OF USE THEREOF
WO2006098918B1 (en) Substituted gamma lactams as therapeutic agents
JP2005504011A5 (en)
RU2007120520A (en) ANALOGUES OF 12-ARILPROSTAGLANDINE
JP2009511599A5 (en)
EP2094678B1 (en) Prostaglandin prodrugs as ocular hypotensive agents
WO2008008660B1 (en) Cyclopentane derivatives as antiglaucoma agents
CA2565660A1 (en) Ortho substituted aryl or heteroaryl amide compounds
WO2008008718B1 (en) Cyclopentane derivatives as antiglaucoma agents
JP6906047B2 (en) Compositions and Methods Related to Salts of Specific Inflammatory Convergent Mediators
AU2009211172A1 (en) Difluorobiphenylamide derivatives for the treatment of ocular hypertension
WO2006043655A1 (en) Medicinal composition for inhalation
CA2535704A1 (en) Aminopropanol derivatives
JP2009543792A5 (en)
WO2008008701B1 (en) Substituted cyclopentane derivatives as therapeutic agents
JP2004502732A5 (en)
AU2014352922B2 (en) Phenylcarbamate derivatives as formyl peptide receptor modulators
RU2003134629A (en) CEPHEMA COMPOUNDS
WO2006121822B1 (en) USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA
WO2008094912B1 (en) Substituted gamma lactams as therapeutic agents
JP5254007B2 (en) Substituted β-lactams and their use in medicine
JP2009506113A5 (en)
CA2502293A1 (en) Ship 1 modulators
WO2008113557A2 (en) Anti-infective agents
WO2006113571B1 (en) Substituted cyclopentanones for treating inflammatory bowel disease

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11569696

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06752286

Country of ref document: EP

Kind code of ref document: A1